Oncolytics Biotech says new pelareorep cancer immunotherapy method — of — use patent issues in several countries

Oncolytics disclosed new method-of-use patents issued in several countries covering pelareorep as an immunotherapy for cancer. U.S. issuance is expected soon, extending planned protection for covered uses into the late 2040s, subject to final claims and terms. Manufacturing patent protection runs through 2044, with three patent application families pending, including additional method-of-use filings. One pending U.S. application is slated for Track One review this quarter, targeting faster examination. A modified “next generation” pelareorep is being developed to support a future composition-of-matter patent with potential 20-year term from filing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via (Ref. ID: 202610121605PRIMZONECNPR____9844130) on October 12, 2026, and is solely responsible for the information contained therein. (C) Copyr